search
Back to results

Feasibility and Preliminary Efficacy of a Reverse Diet as a Novel Weight Loss Maintenance Strategy for Weight-Reduced Adults With Overweight/Obesity

Primary Purpose

Overweight and Obesity, Weight Loss Maintenance, Dietary Habits

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Weight Loss Maintenance (Control vs. Reverse Diet)
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Overweight and Obesity focused on measuring weight loss maintenance, reverse diet, body composition, metabolic rate, dietary adherence, resting energy expenditure, weight loss, weight regain

Eligibility Criteria

21 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All ethnic groups and both genders
  • Age: 21-70 years
  • BMI: 18.5-40 kg/m2
  • Weight loss of >10% body mass achieved within 4 weeks of enrollment in study.

Exclusion Criteria:

  • Uncontrolled cardio metabolic disease such as: cardiovascular disease (CVD), diabetes mellitus, hypertension (defined as: systolic blood pressure >160 mmHg or diastolic blood pressure >100mmHg, as measured during the screening visit with participants seated quietly, following established guidelines), renal disease (e.g. chronic kidney disease, polycystic kidney disease, nephritis, etc.), hepatic disease (e.g. cirrhosis, liver failure, fatty liver, jaundice, etc.), untreated thyroid disease (e.g. Grave's disease, Hashimoto's disorder, goiters, thyroid cancers, etc.), or any other medical condition affecting weight or energy metabolism. Participants who are deemed ineligible based upon uncontrolled hypertension criteria will be referred to their primary care physicians for treatment. If these conditions become controlled they will be allowed to be re-evaluated for inclusion in the current trial.
  • Symptoms suggestive of CVD: chest pain, shortness of breath at rest or with mild exertion, syncope.
  • Significant gastrointestinal disorders including: inflammatory bowel disease requiring treatment within the past year, chronic malabsorptive conditions, chronic diarrhea, or active gallbladder disease.
  • Use of pharmacotherapy agents to achieve weight loss prior to study enrollment.
  • Current treatment with medications known to significantly affect appetite, weight, energy metabolism, energy intake or energy expenditure. (e.g. systemic corticosteroids, appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants).
  • History of surgical or endoscopic procedure for weight loss at any time (e.g. gastroplasty, gastric bypass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve, intragastric balloons, aspiration therapy, etc); history of extensive bowel resection for other reasons.
  • Currently pregnant, lactating or less than 6 months post-partum.
  • Planning to become pregnant during study enrollment period
  • Self-report of alcohol or substance abuse within the past 12 months.
  • History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder, or score >20 on the EATS-26. Participants with a score >20 on the EATS-26 will be referred to their primary care physician for further evaluation.
  • Major psychiatric disorder (e.g. diagnosis of schizophrenia, bipolar disorder, or other psychotic disorders).
  • Current severe depression or history of severe depression within the previous year (based on reported history, study physician examination findings, and/or a score >21 on the CES-D). Participants meeting any of these criteria will be referred to their primary care physician and/or the emergency department (based upon study physician determined level of severity).
  • Currently participating in or planning to participate in any formal weight loss programs or clinical trials.
  • Other medical, psychiatric, or behavioral limitations that may interfere with participation (as determined by study physician).
  • Unable or unwilling to undergo study procedures

Sites / Locations

  • University of Denver, Anschutz Medical Campus

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Control

Reverse Diet

Arm Description

Participants randomized to the CON condition will be informed of their estimated weight maintenance calorie needs (determined by multiplying their resting energy expenditure (REE) obtained from indirect calorimetry by an appropriate activity factor and advised to adhere to this calorie target, as is standard weight maintenance advice. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the diet protocol.

Participants randomized to the reverse diet condition will receive specific caloric intake goals. The initial caloric goal will be set at 2-3% above the level participants ended their weight loss diet at (via self-report). Participants' caloric goals will increase at a rate of 2-3% per week. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the reverse diet protocol.

Outcomes

Primary Outcome Measures

Adherence to the prescribed diet
Self-reported caloric intake compared to prescribed caloric intake
Adherence to the prescribed diet
Evaluated via mathematical model based on change in body mass and composition.
Enrollment Success
The investigators will assess whether they are able to enroll 24 participants meeting study inclusion/exclusion criteria over a 9-month recruitment window. If enrollment is <24, the investigators will determine barriers to enrollment and re-evaluate the study design and/or recruitment strategies. The investigators will also assess participation rate (number approached versus enrolled), reasons potential participants decline enrollment, and ability to meet demographic goals for the larger trial (approximately equal men and women, ≥33% racial and ethnic minorities).
Attrition Rate
The investigators will assess the participant drop-out rate and reasons for attrition over the 12-week study, determine reasons for drop-outs and examine whether drop-out rates differ between intervention arms.

Secondary Outcome Measures

Changes in Body Mass
Measured via calibrated digital scale.
Changes in Body Composition
Measured via Dual-energy X-ray absorptiometry (DXA) scan
Changes in Resting Energy Expenditure
Measured via standard indirect calorimetry with ventilated hood technique
Dietary Adherence
Evaluated via self-report using a measure created by researchers: "How adherent were you to the prescribed diet over the past week?", measured by self-report from 1 (not at all) to 10 (very much so), higher scores indicate higher dietary adherence
Effort
Measure created by researchers: "How hard was it to adhere to the prescribed diet over the last week?" measured by self-report from 1(very easy) to 10 (very difficult) higher scores indicate more expended effort
Self-Efficacy
Measure created by researchers: "How likely do you feel you can adhere to the prescribed diet for the next week?" measured by self-report from 1(not at all likely) to 10 (very likely) higher scores indicate higher self-efficacy
Changes in Food-Related Behaviors
Evaluated via Three-Factor Eating Questionnaire, which is divided into three subscales: Factor One: Dietary Restraint (higher scores indicate higher levels of restrained eating) Factor Two: Dis-inhibition of Control (higher scores indicate higher levels of disinhibited eating) Factor Three: Susceptibility to Hunger (higher scores indicate higher levels of predisposition to hunger)
Changes in Food-Related Behaviors
Evaluated via the Weight Efficacy Lifestyle Questionnaire, which is divided into five subscales: Negative Emotions Availability Social Pressure Physical Discomfort Positive Activities

Full Information

First Posted
May 21, 2018
Last Updated
April 15, 2022
Sponsor
University of Colorado, Denver
search

1. Study Identification

Unique Protocol Identification Number
NCT03560635
Brief Title
Feasibility and Preliminary Efficacy of a Reverse Diet as a Novel Weight Loss Maintenance Strategy for Weight-Reduced Adults With Overweight/Obesity
Official Title
Feasibility and Preliminary Efficacy of a Reverse Diet as a Novel Weight Loss Maintenance Strategy for Weight-Reduced Adults With Overweight/Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
February 14, 2018 (Actual)
Primary Completion Date
January 25, 2022 (Actual)
Study Completion Date
January 25, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this project is to test, for the first time, a reverse diet in adults with current or prior overweight/obesity (Ow/Ob). Weight-reduced adults with current or prior Ow/Ob will be randomized to a reverse diet or "standard care" control (CON) intervention for 12 weeks. Eligible participants will have lost >10% body mass. The reverse diet group will receive personalized caloric intake goals, increasing 2-3%/week. The CON group will receive standard weight maintenance recommendations with matched contact. At baseline and week 12, resting energy expenditure (REE), body mass and composition, subjective appetite, and food intake behaviors will be evaluated. In addition to the pre- and post-intervention measures, body mass and adherence to reverse diet will be monitored weekly.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight and Obesity, Weight Loss Maintenance, Dietary Habits
Keywords
weight loss maintenance, reverse diet, body composition, metabolic rate, dietary adherence, resting energy expenditure, weight loss, weight regain

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Active Comparator
Arm Description
Participants randomized to the CON condition will be informed of their estimated weight maintenance calorie needs (determined by multiplying their resting energy expenditure (REE) obtained from indirect calorimetry by an appropriate activity factor and advised to adhere to this calorie target, as is standard weight maintenance advice. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the diet protocol.
Arm Title
Reverse Diet
Arm Type
Experimental
Arm Description
Participants randomized to the reverse diet condition will receive specific caloric intake goals. The initial caloric goal will be set at 2-3% above the level participants ended their weight loss diet at (via self-report). Participants' caloric goals will increase at a rate of 2-3% per week. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the reverse diet protocol.
Intervention Type
Behavioral
Intervention Name(s)
Weight Loss Maintenance (Control vs. Reverse Diet)
Intervention Description
Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
Primary Outcome Measure Information:
Title
Adherence to the prescribed diet
Description
Self-reported caloric intake compared to prescribed caloric intake
Time Frame
12 weeks
Title
Adherence to the prescribed diet
Description
Evaluated via mathematical model based on change in body mass and composition.
Time Frame
12 weeks
Title
Enrollment Success
Description
The investigators will assess whether they are able to enroll 24 participants meeting study inclusion/exclusion criteria over a 9-month recruitment window. If enrollment is <24, the investigators will determine barriers to enrollment and re-evaluate the study design and/or recruitment strategies. The investigators will also assess participation rate (number approached versus enrolled), reasons potential participants decline enrollment, and ability to meet demographic goals for the larger trial (approximately equal men and women, ≥33% racial and ethnic minorities).
Time Frame
9 months
Title
Attrition Rate
Description
The investigators will assess the participant drop-out rate and reasons for attrition over the 12-week study, determine reasons for drop-outs and examine whether drop-out rates differ between intervention arms.
Time Frame
12 Months
Secondary Outcome Measure Information:
Title
Changes in Body Mass
Description
Measured via calibrated digital scale.
Time Frame
Measured weekly throughout the 12-week trial.
Title
Changes in Body Composition
Description
Measured via Dual-energy X-ray absorptiometry (DXA) scan
Time Frame
At baseline and post intervention (Week 12).
Title
Changes in Resting Energy Expenditure
Description
Measured via standard indirect calorimetry with ventilated hood technique
Time Frame
At baseline and post intervention (Week 12).
Title
Dietary Adherence
Description
Evaluated via self-report using a measure created by researchers: "How adherent were you to the prescribed diet over the past week?", measured by self-report from 1 (not at all) to 10 (very much so), higher scores indicate higher dietary adherence
Time Frame
Measured weekly throughout the 12-week trial.
Title
Effort
Description
Measure created by researchers: "How hard was it to adhere to the prescribed diet over the last week?" measured by self-report from 1(very easy) to 10 (very difficult) higher scores indicate more expended effort
Time Frame
Weekly, throughout the 12-Week Trial
Title
Self-Efficacy
Description
Measure created by researchers: "How likely do you feel you can adhere to the prescribed diet for the next week?" measured by self-report from 1(not at all likely) to 10 (very likely) higher scores indicate higher self-efficacy
Time Frame
Weekly, throughout the 12-Week Trial
Title
Changes in Food-Related Behaviors
Description
Evaluated via Three-Factor Eating Questionnaire, which is divided into three subscales: Factor One: Dietary Restraint (higher scores indicate higher levels of restrained eating) Factor Two: Dis-inhibition of Control (higher scores indicate higher levels of disinhibited eating) Factor Three: Susceptibility to Hunger (higher scores indicate higher levels of predisposition to hunger)
Time Frame
At baseline and post intervention (Week 12).
Title
Changes in Food-Related Behaviors
Description
Evaluated via the Weight Efficacy Lifestyle Questionnaire, which is divided into five subscales: Negative Emotions Availability Social Pressure Physical Discomfort Positive Activities
Time Frame
At baseline and post intervention (Week 12).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All ethnic groups and both genders Age: 21-70 years BMI: 18.5-40 kg/m2 Weight loss of >10% body mass achieved within 4 weeks of enrollment in study. Exclusion Criteria: Uncontrolled cardio metabolic disease such as: cardiovascular disease (CVD), diabetes mellitus, hypertension (defined as: systolic blood pressure >160 mmHg or diastolic blood pressure >100mmHg, as measured during the screening visit with participants seated quietly, following established guidelines), renal disease (e.g. chronic kidney disease, polycystic kidney disease, nephritis, etc.), hepatic disease (e.g. cirrhosis, liver failure, fatty liver, jaundice, etc.), untreated thyroid disease (e.g. Grave's disease, Hashimoto's disorder, goiters, thyroid cancers, etc.), or any other medical condition affecting weight or energy metabolism. Participants who are deemed ineligible based upon uncontrolled hypertension criteria will be referred to their primary care physicians for treatment. If these conditions become controlled they will be allowed to be re-evaluated for inclusion in the current trial. Symptoms suggestive of CVD: chest pain, shortness of breath at rest or with mild exertion, syncope. Significant gastrointestinal disorders including: inflammatory bowel disease requiring treatment within the past year, chronic malabsorptive conditions, chronic diarrhea, or active gallbladder disease. Use of pharmacotherapy agents to achieve weight loss prior to study enrollment. Current treatment with medications known to significantly affect appetite, weight, energy metabolism, energy intake or energy expenditure. (e.g. systemic corticosteroids, appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants). History of surgical or endoscopic procedure for weight loss at any time (e.g. gastroplasty, gastric bypass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve, intragastric balloons, aspiration therapy, etc); history of extensive bowel resection for other reasons. Currently pregnant, lactating or less than 6 months post-partum. Planning to become pregnant during study enrollment period Self-report of alcohol or substance abuse within the past 12 months. History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder, or score >20 on the EATS-26. Participants with a score >20 on the EATS-26 will be referred to their primary care physician for further evaluation. Major psychiatric disorder (e.g. diagnosis of schizophrenia, bipolar disorder, or other psychotic disorders). Current severe depression or history of severe depression within the previous year (based on reported history, study physician examination findings, and/or a score >21 on the CES-D). Participants meeting any of these criteria will be referred to their primary care physician and/or the emergency department (based upon study physician determined level of severity). Currently participating in or planning to participate in any formal weight loss programs or clinical trials. Other medical, psychiatric, or behavioral limitations that may interfere with participation (as determined by study physician). Unable or unwilling to undergo study procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tanya Halliday, PhD
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Denver, Anschutz Medical Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Feasibility and Preliminary Efficacy of a Reverse Diet as a Novel Weight Loss Maintenance Strategy for Weight-Reduced Adults With Overweight/Obesity

We'll reach out to this number within 24 hrs